Vera Therapeutics is trading 4.3% down at $29.85; no company-specific news clearly explains the decline amid AI-spending concerns and rising oil prices amid geopolitical tensions.
- Reuters reported the Nasdaq slid more than 2% on October 22 as growth stocks weakened; oil’s recovery added unease.
- Positive ORIGIN 3 final efficacy results met the primary endpoint October 22; presented at ASN Kidney Week and published in the New England Journal of Medicine.
- The webcast was scheduled for 4:30 p.m. ET, after the 1:52 p.m. price snapshot.